REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
 
|
|
Drug, Bio-affecting And Body Treating Compositions > Enzyme Or Coenzyme Containing > Multienzyme Complexes Or Mixtures Of Enzymes Multienzyme Complexes Or Mixtures Of EnzymesMultienzyme Complexes Or Mixtures Of Enzymes patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/09/07 - 20070184042 - Method of cancer treatment by p53 protein control Method of cancer treatment by controlling cellular p53 protein levels. The invention concerns, in particular, the use of a compound capable of modulating calpaine activity. ... 06/28/07 - 20070148150 - Mkk7 activation inhibitor PAK4 and JIK, both of which bind to MKK7 and directly phosphorylate MKK7, were found in the present invention. The present invention provides an inhibitor of c-Jun phosphorylation caused by JNK3 and a method for inhibiting the same, and an agent for preventing and/or treating a disorder attributable to c-Jun ... 06/21/07 - 20070141040 - Protein kinase c peptide modulators of angiogenesis The present invention provides peptides for inhibiting various protein kinase C isozymes. The peptide can be directed to any region of the protein kinase C isozyme, and in one embodiment, is directed to the V5 domain. The peptide can be conjugated to a carrier, in a releasable or non-releasable manner. ... 05/31/07 - 20070122401 - Methods and compositions for modulating telomerase reverse transcriptase (tert) expression Nucleic acid compositions comprising an Ikaros or WT1 repressor binding site that act to repress transcription of the telomerase reverse transcriptase (TERT) coding sequence, as well as vectors and constructs including the same, are provided. Also provided are methods of modulating, e.g., inhibiting, the TERT transcription repressing activity of the ... 05/24/07 - 20070116695 - Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders A pharmaceutical preparation for the treatment of attention deficit disorders combines a therapeutically effective amount of digestive enzymes, such as chymotrypsin, and medication used to treat attention deficit disorders, such as Ritalin®, Concert®, Adderall® and Strattera®. The preparation may be in the form of a tablet, capsule or time released ... 05/24/07 - 20070116694 - Inhibitor of interaction of granzyme b with golgin-160 It is an object of the present invention to find a protein interacting with Granzyme B and to provide a means for preventing and/or treating diseases caused by the decomposition of the above protein by Granzyme B. The present invention provides a method of using Golgin-160 as a substrate of ... 05/03/07 - 20070098707 - Methods and compositions for inhibiting c-met dimerization and activation The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met antagonist that disrupts c-met multimerization. ... 04/26/07 - 20070092501 - Compositions and methods relating to reduction of symptoms of autism Methods and compositions that can reduce the symptoms of autism in a human patient comprising administering a physiologically effective amount of one or both of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, and a physiologically effective amount of a purified gluteomorphin ... 03/08/07 - 20070053895 - Method of treating and diagnosing parkinsons disease and related dysautonomic disorders A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease ... 03/08/07 - 20070053894 - Compound and method for regulating plasminogen activation and cell migration The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compositions form regulating cell migration, plasminolysis, angiogenesis and for treating cancer. In particular, ... 02/22/07 - 20070041959 - Poly-pegylated protease inhibitors Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one ... 02/15/07 - 20070036777 - Stabilized pancreas product The present invention provides stabilized pancreas products useful, for example, as an animal feed additives. The invention also provides for feed additives and feed rations comprising a stabilized pancreas product. Further, the invention provides for methods of making stabilized pancreas products. The present invention also provides for methods of supplementing ... 02/08/07 - 20070031395 - Repressor of skeletal muscle differentiation, nucleic acid coding therefor and the use thereof in diagnosis and therapy Polypeptide sequences which play a part in the regulation of skeletal muscle differentiation, and nucleic acids coding therefor, and the use thereof in diagnosis and therapy are disclosed. Possible uses are also indicated for antibodies which are directed against corresponding epitopes of the GRIM1 polypeptide. ... 01/25/07 - 20070020252 - Modified protease inhibitors DX-890 inhibits elastase. DX-890 can be attached a single polyethylene glycol moiety. The polyethylene glycol is at least 18 kDa in molecular weight and is attached to the polypeptide by a single covalent bond to the N-terminus of the polypeptide. ... 01/18/07 - 20070014776 - Identification of adiponutrin-related proteins as esterases and methods of use for the same The present invention provides methods of identifying polypeptides that have enzymatic activity associated with nutrient and/or energy homeostasis, and thus, are involved in the development of one or more cardiovascular and metabolic disorders, e.g., cardiovascular disease, obesity, insulin resistance, type 2 diabetes, dyslipidemia, nonalcoholic fatty liver disease, and metabolic syndrome. ... 01/04/07 - 20070003535 - Methods and compositions for derepression of iap-inhibited caspase The invention provides isolated agents having novel chemical structures and possessing superior activity as derepressors of IAP inhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase. The invention further provides assay methods employing labeled compounds of the invention, especially fluorescent labeled compounds. ... 01/04/07 - 20070003534 - Protein forming complex with c-jun protein, nucleic acid encoding the same and method of using the same Comprehensive analysis of transcription control factor complexes in a mouse brain cDNA library with c-Jun as a bait by using the cotranslation selection and screening of in vitro virus (IVV) and the C-terminal labeling method are conducted, thereby to provide known and unknown proteins which are unknown to form a ... 12/21/06 - 20060286084 - Agent for promoting osteogenesis and/or inhibiting bone resorption Provided is a novel agent for promoting osteogenesis and/or inhibiting bone resorption, which: can be directly taken from daily meals by mouth for long periods without any trouble in taste; directly impart a promoting effect on osteogenesis and an inhibiting effect on bone resorption to the bone; and can be ... 12/07/06 - 20060275277 - Use of coagulation proteins to lyse clots The present invention relates to the use of coagulation proteins for the lysis of blood clots. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of at least one coagulation protein comprising a basic C-terminal amino acid, wherein the coagulation ... 11/30/06 - 20060269536 - Inhibitor proteins of a protease and use thereof The present invention relates to a chimeric inhibitor protein of a protease comprising an inhibiting polypeptidic sequence and at least one polypeptidic sequence of a substrate-enzyme interaction site specific for a protease. Other objects of the invention are to provide a purified and isolated DNA sequence encoding the chimeric inhibitor ... 11/02/06 - 20060246047 - Peptide wirh apoptosis-inhibiting activity A peptide consisting of part of the amino acid sequence of SEQ ID No: 8 and having an amino acid sequence of SEQ ID No: 1 or SEQ ID No: 2, e.g., a peptide consisting of the amino acid sequence of any one of SEQ ID Nos: 1 to 5, ... 11/02/06 - 20060246046 - Modified tridegins, production and use thereof as transglutaminase inihibitors The invention relates to modified tridegins, polypeptides derived from SEQ ID No. 1, in which the modification is replacement of a cysteine residue and/or one of the following amino acids—Lys2, Lys7, His10, Gly12, Leu24, Tyr31, Phe34, Arg39, Ile45, Met48, Asp50, Pro55, Phe58, Asn60, Pro65, Arg66, by another amino acid and/or ... 10/19/06 - 20060233779 - Ring finger family proteins and uses related thereto The application provides, among other things, specificity domains, and methods for identifying and using specificity domains. ... 10/19/06 - 20060233778 - Stability for injection solutions A primary package containing a low molecular weight peptide-based thrombin inhibitors which package is sealed with a rubber stopper or plunger containing bromobutyl rubber. ... 10/19/06 - 20060233777 - Use of bacteriocin for the amelioration of digestive functionality The subject of the present invention is the use of bacteriocins and/or their producer strains for the amelioration of digestive functionality and for the amelioration of gastrointestinal tract conditions in monogastric organism species. ... 09/28/06 - 20060216280 - Fibrinogen-based tissue adhesive containing an elastase inhibitor The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor. ... 09/28/06 - 20060216279 - Myostatin inhibiting fusion polypeptides and therapeutic methods thereof Myostatin inhibiting GDF8 and GDF11 fusion polypeptides and their encoding nucleic acids are disclosed. Pharmaceutical compositions comprising these fusion polypeptides or their corresponding nucleic acids and methods of use are also disclosed. ... 09/21/06 - 20060210547 - Dna encoding anti-apoptotic protein and recombinant 30k protein The present invention relates to DNAs encoding anti-apoptotic 30K proteins. More particularly, the present invention is directed to 30K protein genes and a recombinant proteins prepared by using novel anti-apoptotic gene obtained from silkworm. The present invention also provides anti-apoptotic health care food, pharmaceutical preparation, additive for cell culture medium, ... 09/14/06 - 20060204486 - Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases The invention relates to new pharmaceutical compositions for the treatment and/or prevention of schizophrenia and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment ... 09/07/06 - 20060198832 - Peptide drugs for chronic lymphocytic leukemia (cll) and other cancers The present invention provides a modified BAD peptide or peptidomimetic which includes an amino acid sequence having at least 60% amino acid identity with SEQ ID NO: 1, where the modified BAD peptide or peptidomimetic has enhanced affinity for Bcl-2 as compared to wild type BAD peptide (SEQ ID NO: ... 08/31/06 - 20060193844 - Methods for enzyme inhibition Improved regimens for administering proteasome inhibitors are described, wherein proteasome inhibition is more sustained relative to certain current regimens which permit substantial recovery of proteasome activity between doses of inhibitor. ... 08/10/06 - 20060177432 - Methods and reagents for protease inhibition The invention discloses a protease inhibitor and a method of inhibiting a protease selected from the group consisting of thrombin, chymotrypsin and neuropsin, by contacting the protease with an effective amount of a member of the phosphoethanolamine binding protein (PEBP) family. ... 08/10/06 - 20060177431 - Inhibitors for continuous activation of calcineurin The object of the present invention is to provide a suppressant for neuronal cell death effective for various diseases which inhibits a constitutive active forming of calcineurin and has less side effect. An inhibitor of constitutive active forming of calcineurin, more specifically a drug which inhibits cleavage of calcineurin subunit ... 07/06/06 - 20060147439 - Agent and compositions comprising the same for inhibiting lipases and phospholipases in body fluids, cells and tissues The present invention deals with a protein and compositions comprising the same for inhibition of lipases and phospholipases in the body fluids, cells, and tissues for the prevention and treatment of metabolic syndrome, cardiovascular disorders, and inflammatory diseases. The protein is either isolated from plant species or synthesized or produced ... 06/29/06 - 20060140926 - Mss4 as an antifungal target The invention provides 1-phosphotidylinositol-4-phosphate 5-kinase (MSS4) as a novel antifungal target, screening methods for MSS4 inhibitors and their use as antifungal compounds, pharmaceutical compositions containing them and their use in medicine. ... 06/22/06 - 20060134087 - Iti-d1 kunitz domain mutants as hne inhibitors Mutants of Kunitz domain 1 (ITI-D1) of human inter-α-trypsin inhibitor (ITI), are useful as inhibitors of human neutrophil elastase. Mutants characterized by one or more of the following substitutions (numbered to correspond to bovine pancreatic trypsin inhibitor, the archetypal Kunitz domain) are of particular interest: (a) Val15 or Ile15, (b) ... 06/15/06 - 20060127385 - Method for sustaining enos activity The present invention is directed to methods for sustaining eNOS activity to inhibit platelet aggregation, clot retraction, and enhance fibrinolysis. One embodiment of the invention provides methods of treating thrombosis by inhibiting the activity of the syk kinase. Another embodiment provides assays for the discovery of improved compounds to treat ... 06/08/06 - 20060121017 - Compositions and methods for treating pancreatic insufficiency The present invention relates to compositions for the treatment of conditions, including pancreatic insufficiency. The compositions of the present invention comprise lipase, protease and amylase in a particular ratio that provides beneficial results in patients, such as those afflicted with pancreatic insufficiency. This invention also relates to methods using such ... 06/01/06 - 20060115467 - Compositions and methods for the treatment of autism Compositions that may be usefully employed to alleviate symptoms resulting from deficiencies in carbohydrate enzymes, together with methods for the treatment of disorders that are characterized by such deficiencies, such as autism, are provided. The compositions preferably comprise transglucosidase isolated from A. niger. ... 05/04/06 - 20060093598 - Stabilized liquid polypeptide-containing pharmaceutical compositions Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. Methods for increasing stability of ... 05/04/06 - 20060093597 - Methods of treating involuntary facial spasms and facial wrinkles The invention describes antibiotics, muscle relaxants and plant extracts that have neuromuscular blockade effects as well as methods of use thereof. These compounds can be used in the same clinical settings as botulinum toxin and may be used topically, thereby providing an advantage over botulinum toxin in terms of application ... 05/04/06 - 20060093596 - Genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish There is provided a method of identifying candidate nucleic acid sequences encoding antimicrobial peptides. The method comprises: identifying an initial peptide of interest; identifying genomic DNA encoding the initial peptide; identifying a flanking sequence on each side of the initial peptide; obtaining primers complementary to the flanking sequences; and, screening ... 05/04/06 - 20060093595 - Methods, compositions and kits for treating damage to excitable tissue Drug cocktails including protease inhibitors, sodium channel blockers and corticosteroids are described. The use of these drug cocktails in treatment of damage due to injury to excitable tissue is discussed. The use of the drug cocktails in the treatment or prevention of degenerative conditions of the central nervous system and ... 04/13/06 - 20060078551 - Novel therapeutic and prophylactic agents and methods of using the same A phospholipase A2 inhibitor protein designated “Phospholipase Inhibitor from Python” (PIP)—formerly designated “Python Antitoxic Factor” (PAF)—is given by SEQ ID NO:2. The partial amino acid sequence for PIP was initially determined from the native protein purified from the blood serum of a non-venomous snake, Python reticulatus. The complete PIP polynucleotide ... 04/13/06 - 20060078550 - Porcine fgl2 The present invention relates to porcine fgl2 gene and protein and methods of modulating the gene and protein. The methods are useful in preventing thrombosis associated with the xenotransplantation of porcine organs or tissues. ... 04/06/06 - 20060073132 - Agents for wound healing The present invention relates to pharmaceutical compositions containing fragments of alpha-1 proteinase inhibitor (API) or chimeric proteins of API and insulin-like growth factor for use in stimulating wound healing. ... 03/23/06 - 20060062775 - Method for the production of protamine The present invention generally relates to the fields of genetic engineering and biochemistry. In particular, it relates to a novel method for the production of protamine as well as to novel method for the production of protamine as well as to novel compositions containing protamine as active ingredient. Furthermore, it ... 03/16/06 - 20060057133 - Topical pathogenic-tissue-destroying liquid The invention relates to a method of producing a pharmaceutical composition, consisting in mixing nitric acid in composition with mucin and ptyalin enzymes which are used as absorbers. Together, said components produce a topical aqueous solution which destroys pathogenic tissue, by coagulating same, in order to treat a patient with ... 03/09/06 - 20060051336 - Bacteriolytic complex, method of its production, and strain for realization of the method The inventions relate to the field of medicine, veterinary and biotechnology and may be used for production of a drug for medical and veterinary purposes. A bacteriolytic complex, produced by the bacterium Lysobacter sp. XL1, has been proposed, which contains bacteriolytic enzymes (muramidase, muramoylalanineamidase, endopeptidase, a bacteriolytic enzyme with a ... 01/05/06 - 20060002912 - Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis The invention relates generally to methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis (ERCP). The method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier. ... 12/22/05 - 20050281795 - Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers There is provided a composition comprising at least one mucoadhesive polymer that is capable of forming a hydrogel and at one least water soluble polymer, and one or more enzymes, microorganisms, or antibodies. The formulation forms a hydrogel in aqueous solution that has mucoadhesive properties and that is capable of ... 11/10/05 - 20050249714 - Method of using secretin and compositions made therefrom for the treatment of autism and other neurological, behavioral and immunological disorders Secretin and secretin compositions are used for the treatment of autism and other neurological, behavioral and immunological disorders. The method includes administering an effective amount of secretin, such as Secretin-Ferring, to a patient. In one example, 2 clinical units (CU) of Secretin-Ferring was dissolved in a 7.5 ml solution of ... 11/03/05 - 20050244397 - Process for prolonging the after-harvest life of citrus fruit A formulation is provided for preventing fungus on citrus fruits to prolong the life of the fruits after harvesting. The formulation is based on a combination of safe organic enzymes and catalysts by utilizing natural microbal action to break down carbohydrate forming cell walls by consuming and digesting the offending ... 11/03/05 - 20050244396 - Application of a non-toxic organic enzyme formulation and process for reducing fungi-caused decay on fruits and vegetables An enzyme formulation is provided for preventing fungi and their proteins from forming on fruits and vegetables, and for extending the shelf life of the fruits and vegetables from field (pre-harvest) to various post-harvest points, such as packing houses, processing operations, distribution points, shippers, retailers and consumers. The enzyme formula ... 10/27/05 - 20050238634 - Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent ... 09/15/05 - 20050201999 - Compounds and methods for identifying compounds which inhibit a new class of aspartyl proteases Compounds and methods for designing and identifying compounds which inhibit TFPP-like aspartyl protease enzymes by targeting the aspartic acid residues of the active site or mimicking peptides corresponding to the region surrounding the substrate's cleavage site are provided. Agents identified as inhibitors of TFPP-like aspartyl proteases such as type 4 ... 09/15/05 - 20050201998 - Novel multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders The present invention provides compositions and methods for preventing and treating gastrointestinal disorders by administering to a subject an effective amount of secretin either alone or in combination with an effective amount of oxytocin. The invention also provides compositions and methods for preventing and treating central nervous system disorders by ... 08/11/05 - 20050175600 - Wound healing compositions and methods using tropoelastin and lysyl oxidase The present invention provides compositions and methods for promoting wound healing. The composition comprises virgin monomers of tropoelastin and lysyl oxidase. When the lysyl oxidase comes in contact with the tropoelastin, cross-linking of the tropoelastin monomers will occur to form elastin. Contacting the tropoelastin and lysyl oxidase together and applying ... 07/28/05 - 20050163765 - Granulates containing feed-enzymes The present invention describes a process for the preparation of an enzyme-containing granulate wherein an aqueous enzyme-containing liquid is, optionally supplemented with a solid carrier and/or additive ingredients, processed into granules, dried and subsequently coated with a polyolefin, preferably polypropylene and/or polyethylene. This coated enzyme granulate is suitable for the ... 07/14/05 - 20050152887 - Protonic formulation A stabilized protonic mixture having a protonic formulation (FIG. 2A) comprised primarily of proteins (FIG. 2A), enzymes and pH adjusters (FIG. 2A), all in specific ratios to one another; a liquid medium which, when combined to the protonic formulation, initiates activation of the amino acids within the protonic formulation; and ... 06/16/05 - 20050129675 - Methods for treatment of acute pancreatitis The invention relates generally to methods for treating acute pancreatitis in patients. The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier. ... ### FreshPatents.com Support - Terms & Conditions |